# A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

> **NCT02969525** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 206 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **OTHER:** Placebo
- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT02969525
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-11
- **Final completion:** 2018-07
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02969525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02969525, "A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02969525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*